Welcome to our dedicated page for Cuprina Holdings (Cayman) SEC filings (Ticker: CUPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cuprina Holdings (Cayman)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cuprina Holdings (Cayman)'s regulatory disclosures and financial reporting.
Cuprina Holdings (Cayman) LTD director KOH Pee Keat filed a Form 3 insider report for CUPR. The filing lists no buy, sell, acquire, or dispose transactions and shows no derivative positions in this dataset. It functions as a baseline insider ownership disclosure for this director.
Cuprina Holdings (Cayman) LTD director Teo Peng Kwang reported his existing indirect ownership of Class B Ordinary Shares. The filing shows 5,818,504 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. are attributed to him through his 41.31% interest in that entity, which in total holds 14,085,000 Class B Ordinary Shares. This Form 3 records holdings rather than any new share purchases or sales.
Cuprina Holdings (Cayman) LTD director files initial ownership report. Natasha Kaur Raina, a director of Cuprina Holdings (Cayman) LTD (ticker CUPR), submitted a Form 3, which is an initial statement of beneficial ownership of securities. The filing shows no reported transactions or derivative positions.
Cuprina Holdings (Cayman) LTD director and 10% owner LEE Jimmy Peng Siew filed an initial Form 3 reporting his indirect holdings in Class B Ordinary Shares. The filing shows 5,146,638 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. as the relevant block attributed to him.
Cuprina Holding Pte. Ltd. holds an aggregate of 14,085,000 Class B Ordinary Shares of the company, and Mr. LEE owns a 36.54% ownership interest in that entity. The filing records this position as indirect ownership, with no reported purchases, sales, or option exercises.
Cuprina Holdings (Cayman) Limited has called a May 14, 2026 annual general meeting to vote on wide‑ranging governance and capital structure changes. The board seeks approval for a share consolidation affecting both Class A and Class B Ordinary Shares to help regain compliance with Nasdaq’s $1.00 minimum bid rule.
Shareholders are asked to increase Class B voting power from 10 to 100 votes per share, double authorised capital after the consolidation, adopt new second amended and restated constitutional documents, and approve the Cuprina 2026 Employee Incentive Plan covering up to 15% of Class A shares. A key proposal would authorise future financings that may exceed 20% of outstanding Class A Ordinary Shares or result in a change of control under Nasdaq rules, potentially diluting existing holders.
Cuprina Holdings (Cayman) LTD director files initial ownership report with the SEC. NG Wei Chean is identified as a director of CUPR, but this Form 3 excerpt shows no reported transactions or specific share or derivative holdings for this insider.
Cuprina Holdings reports a key regulatory milestone and a governance upgrade. Its 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, a medical-grade maggot debridement therapy. The SFDA has categorized MEDIFLY as a Medical Device–Drug combination product, primarily regulated under the medical device framework. This classification enables Cuprina to finalize scientific and technical requirements needed for commercial distribution across Saudi Arabia’s healthcare network, supporting its Middle East and North Africa expansion strategy.
The company also strengthened its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, a consultant in endocrinology at Tan Tock Seng Hospital and Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine in Singapore. Under a strategic advisory agreement, Dr. Yong will guide scientific and development strategy, clinical oversight, strategic consultation, and trend analysis in endocrinology and chronic wound management, reinforcing Cuprina’s focus on patient safety and clinical excellence.
Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory. The joint venture is intended to develop and market a novel iodine-based solution as a new wound care therapy. The press release describing this collaboration is included as Exhibit 99.1 to this Form 6-K.
Cuprina Holdings (CUPR) reported a change in its independent registered public accounting firm. The board dismissed Kreit & Chiu CPA LLP effective October 15, 2025, and appointed J&S Associate PLT as successor auditor to audit the consolidated financial statements for the fiscal year ending December 31, 2025. The audit committee approved the appointment.
K&C’s audit reports for 2024 and 2023 contained no adverse opinions or disclaimers and were not qualified or modified. The company stated there were no disagreements with K&C on accounting principles, disclosure, or audit scope during the two most recent fiscal years and through October 14, 2025, and no reportable events as defined in Item 16F(a)(1)(v) of Form 20-F. A letter from K&C addressing the disclosure was filed as an exhibit.
Cuprina Holdings (Cayman) Limited filed a Form 6-K to share that, on September 9, 2025, it issued a press release announcing that Cuprina has secured exclusive rights to Southeast Asia’s first medical waste recycling technology demonstrated by UNIDO and the Global Environment Facility (GEF). The report mainly serves as a regulatory notice that this press release has been furnished as an exhibit.